A. The mouse aortocaval fistula recapitulates human arteriovenous fistula maturation. Am J Physiol Heart Circ Physiol 305: H1718 -H1725, 2013. First published October 4, 2013 doi:10.1152/ajpheart.00590.2013.-Several models of arteriovenous fistula (AVF) have excellent patency and help in understanding the mechanisms of venous adaptation to the arterial environment. However, these models fail to exhibit either maturation failure or fail to develop stenoses, both of which are critical modes of AVF failure in human patients. We used high-resolution Doppler ultrasound to serially follow mice with AVFs created by direct 25-gauge needle puncture. By day 21, 75% of AVFs dilate, thicken, and increase flow, i.e., mature, and 25% fail due to immediate thrombosis or maturation failure. Mature AVF thicken due to increased amounts of smooth muscle cells. By day 42, 67% of mature AVFs remain patent, but 33% of AVFs fail due to perianastomotic thickening. These results show that the mouse aortocaval model has an easily detectable maturation phase in the first 21 days followed by a potential failure phase in the subsequent 21 days. This model is the first animal model of AVF to show a course that recapitulates aspects of human AVF maturation. aortocaval fistula; arteriovenous fistula; maturation; mouse; model THE ARTERIOVENOUS FISTULA (AVF) is the most common access chosen for hemodialysis as the first-line therapy before renal replacement. Despite the superiority of AVF access compared with its alternatives, AVFs are still far from perfect. AVFs fail to "mature," e.g., dilate, thicken, and increase flow, before the beginning of dialysis in ϳ20 -50% of cases, with the majority of AVFs requiring some additional therapeutic intervention to mature successfully (9, 14, 20, 21) . In addition, 1-yr primary AVF patency rates are typically only 60 -65%, with many mature AVFs subsequently failing secondarily due to neointimal hyperplasia, generally perianastomotic (2, 4, 7, 19, 21, 22) . The poor patency of AVFs clearly reflects our imperfect understanding of the biology of venous remodeling to the arterial environment.
THE ARTERIOVENOUS FISTULA (AVF) is the most common access chosen for hemodialysis as the first-line therapy before renal replacement. Despite the superiority of AVF access compared with its alternatives, AVFs are still far from perfect. AVFs fail to "mature," e.g., dilate, thicken, and increase flow, before the beginning of dialysis in ϳ20 -50% of cases, with the majority of AVFs requiring some additional therapeutic intervention to mature successfully (9, 14, 20, 21) . In addition, 1-yr primary AVF patency rates are typically only 60 -65%, with many mature AVFs subsequently failing secondarily due to neointimal hyperplasia, generally perianastomotic (2, 4, 7, 19, 21, 22) . The poor patency of AVFs clearly reflects our imperfect understanding of the biology of venous remodeling to the arterial environment.
The AVF has been studied using several models, including the surgical anastomosis model as well as the puncture model (1, 5, 6, 8, 10 -12, 15-17) . All of these models have strengths and weakness, including technical difficulty due to surgery as well as the use of animals larger than mice (1, 5, 8, 12, 15, 16) . A common feature of all these models is that they are good models of surgical access, with good patency; unfortunately, they fail to exhibit a percentage of animals that either fail to mature or fail to develop stenoses in long-term followup, both of which are both important aspects of understanding modes of failure of human AVF.
Recent advances in ultrasound technology have allowed increasingly accurate analysis of blood flow within small vessels, such as in a mouse, as well as allowing the ability to serially examine the same mouse over time. We used this technology to observe the time course of venous remodeling in the mouse aortocaval puncture model (23) to determine whether this model is an accurate model of human AVF maturation and, in particular, whether a certain percentage of animals fail to mature successfully.
MATERIALS AND METHODS
Antibodies. Antibodies against mouse CD31 (PECAM-1) were raised in rabbits and purified as previously described elsewhere (18) . Rabbit polyclonal antibodies against mouse ␣-smooth muscle actin (␣-actin, ab5694) and Ki-67 (ab15580) were purchased from Abcam (Cambridge, MA).
Anesthesia and surgery. All animal experiments were performed in strict compliance with federal guidelines and with approval from the Institutional Animal Care and Use Committee of Yale University. The appropriate anesthesia and analgesia were given as described in our previous study (23) . Male C57/BL6 mice (age: 10 wk and body weight: 20 -30 g) were used for this study.
Briefly, 4% isoflurane in 0.8 l/min O 2 was delivered via an isoflurane vaporizer for induction and decreased to 2-3% after mice were anesthesized. Under general anesthesia, a midline laparotomy was made, and the aorta and inferior vena cava (IVC) were exposed. The proximal infrarenal aorta and distal aorta were dissected for clamp placement and needle puncture, respectively; the vena cava was not dissected free from the aorta. After the aorta was clamped just below the left renal artery, a 25-gauge needle was used to puncture the aorta through into the IVC. The surrounding connective tissue was used for hemostatic compression. Successful creation of the AVF ("technical success") was characterized by hemostasis as well as visible pulsatile arterial blood flow in the IVC.
Ultrasound. We performed Doppler ultrasound both pre-and postoperatively to confirm the presence of the AVF and to measure the sizes of the aorta, IVC, and heart. The Vevo770 High Resolution Imaging System (VisualSonics) with probe RMV704 was used under general anesthesia as described above. For confirmation of an AVF, the waveform in the IVC was recorded using pulse-wave mode. The presence of arterial or turbulent waveforms in the IVC that were not detected before the AVF surgery was regarded as a patent AVF.
The diameters of the aorta and IVC just above, cranial to the renal veins, were recorded, as was the diameter of the heart at maximal diastole. Ultrasound testing was performed on preoperative day 1 and on postoperative days 1, 7, 14, 21, 28, 35 , and 42. Flow velocity was measured by ultrasound, and shear stress was calculated using the Hagen-Poiseuille equation (13) . The following equation was used: T ϭ 4V/r, where T is shear stress, is blood viscosity, V is flow velocity (in cm/s), and r is the radius (in cm). Blood viscosity was assumed to be constant at 0.035 poise. Histology. After euthanasia, the AVF was extracted en bloc after a circulatory flush with PBS followed by 10% formalin. The tissue block was then embedded in paraffin and cut into 5-m crosssections. Hematoxylin and eosin as well as elastin van Gieson staining were performed for all samples.
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For intima-media thickness measurements, samples were cut at 50 -100 m cranial to the fistula and stained with elastin van Gieson. The thickness was measured at eight equidistant points per crosssection and then averaged.
Immunohistochemistry. Immunohistochemistry was performed using the Dako EnVisionϩ Dual Link System-HRP (Dako, Carpinteria, CA). For antigen retrieval, sections were heated in citric acid buffer (pH 6.0) at 100°C for 10 min using the Lab Vision PT Module (Thermo Scientific, Kalamazoo, MI). Sections were treated with 0.3% hydrogen peroxide in methanol for 30 min at room temperature to block endogenous peroxidase activity and incubated with 5% normal goat serum in PBS (pH 7.4) containing 0.05% Triton X-100 for 1 h at room temperature to block nonspecific protein-binding sites. Sections were then incubated at 4°C with the primary antibodies diluted at 1:100 (anti-␣-actin and Ki-67) and 1:200 (anti-CD31) in PBS containing 0.05% Triton X-100. After an overnight incubation, sections were incubated with EnVision reagents for 1 h at room temperature and treated with the Dako Liquid DABϩ Substrate Chromogen System (Dako) to visualize the reaction products. Finally, sections were counterstained with Dako Mayer's Hematoxylin (Lillie's Modification) Histological Staining Reagent (Dako).
Blood gas experiments. PO 2 in the IVC was measured using the i-STAT system (Abbott Laboratories). Blood samples were drawn from the infrarenal IVC, e.g., the venous limb of the AVF, while animals were under anesthesia (97-98% O 2) before samples were harvested.
RNA extraction and quantitative PCR. Total RNA from the venous limb of the AVF was isolated using the RNeasy Mini kit with digested DNase I (Qiagen); care was taken to avoid the surrounding arterial tissue. RNA quality was confirmed by the 260-to-280-nm ratio. Reverse transcription was performed using the SuperScript III FirstStrand Synthesis Supermix (Invitrogen). Real-time quantitative PCR was performed using SYBR Green Supermix (Bio-Rad Laboratories) and amplified for 35 cycles using the iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories). Correct target amplification and exclusion of nonspecific amplification was confirmed by 1.5% agarose gel electrophoresis, and primer efficiencies were determined by meltcurve analysis. All samples were normalized by GAPDH RNA amplification.
Statistical analysis. All data were analyzed using JMP 9.0 software (SAS Institute). Comparison between groups was performed with multivariate ANOVA followed by post hoc tests. P values of Ͻ0.05 were considered significant.
RESULTS

Assessment of fistula technical success.
AVFs were created in the mouse between the aorta and IVC as previously described (23) . Successful technical creation of a patent AVF was assessed by several methods. First, intraoperatively, after hemostasis was obtained, visual inspection confirmed bright arterial blood flowing turbulently into the IVC through the AVF. Postoperatively, noninvasive Doppler ultrasound was used to examine the AVF. Definitions of the anatomy of the IVC in this study are shown in Fig. 1A . Caudal to the fistula, the Doppler waveform possessed typical venous morphology; at the AVF, the waveform was arterial with spectral broadening suggesting turbulence. Cranial to the AVF, the waveform was arterial, with diminished peak velocities compared with those at the AVF (Fig. 1B) . Histological assessment of the AVF showed a patent fistula between the aorta and IVC (Fig.  1C) . After 21 days, the AVF showed overgrowth of aortic tissue into the IVC, suggesting the perianastomotic neointimal hyperplasia that is typically seen in human AVF (asterisk in Fig. 1C) .
Physiological assessment of the AVF was performed. Mice with patent AVFs showed significantly higher PO 2 in the infrarenal IVC, e.g., the venous limb of the AVF, compared with sham mice without AVF; there were no differences in PCO 2 (Fig. 1D) . In addition, mice with AVFs showed significantly increased osteopontin mRNA expression compared with sham mice (Fig. 1E) ; osteopontin typically increases significantly in AVFs (3).
The survival of mice after AVF or sham surgery is shown in Fig. 2A . Early deaths were typically due to postoperative hemorrhage. After successful AVF surgery, these mice typically showed dilated abdominal wall veins (Fig. 2B) as well as dilation of the distal IVC (Fig. 2C) , consistent with lower limb venous congestion from the AVF.
Cardiac diameter was assessed using ultrasound, showing enlargement in mice with AVFs compared with those with sham surgery (Fig. 2D) . However, dilated cardiac diameter was not associated with any morphological signs of cardiac failure, including increased body weight (Fig. 2E ) or late death ( Fig. 2A) , consistent with minimal systemic toxicity from the AVF.
AVF patency over time. Technical success was defined as visualization of arterial blood easily flowing into the IVC at the end of surgery. Technical success was assessed after each group of 50 procedures and was noted to increase with time, suggesting a learning curve for this surgical model (Fig. 3A) .
Long-term patency of the AVF was assessed only in mice with a technically successful AVF after the procedure (Fig.  3B) . In ϳ25% of the mice with a technically successful AVF on day 0, the AVF had no detectable flow on day 1, probably due to immediate thrombosis or very low flow velocity. Between days 1 and 28, some of the AVFs showed patency despite no detectable flow in the AVF on day 1. On the other hand, some of the AVFs that were patent on day 1 were Fig. 3 (Fig. 3B) , with all the mice grouped into five groups according to their technical success, immediate thrombosis, and patency at days 21 and 42 (Fig. 4) . Although the results shown in Fig. 4 reflect the general behavior of the AVF course, not shown is the potential for recanalization and increased flow of an AVF that was thought to be thrombosed or have low flow on day 1.
AVF measurements. Doppler ultrasound was used to serially examine the aortic and suprarenal IVC diameter in mice with AVF or sham procedures. After 21 days, mice with patent AVFs ("maturation success") were characterized by dilation of the suprarenal IVC cranial to the AVF (38% increase) as well as of the aorta proximally leading into the AVF (27% increase). After 42 days, mice with patent AVFs ("AVF success") had dilation of both the aorta (Fig. 5A, shaded bars) as well as suprarenal IVC (Fig. 5B, shaded bars) ; however, AVFs that were initially patent at day 21 and then ultimately failed by day 42 ("AVF failure") had no significant differences in either aortic or IVC diameters from sham mice at day 42 (Fig. 5, A and B, hatched bars). In this AVF failure group, both aortic and IVC diameters were increased significantly at day 21, similar to the AVF success group (data not shown), suggesting that the lack of difference between sham and AVF failure diameters at day 42 (Fig. 1, A and B, open and hatched bars) were not due to lack of any dilation in the AVF failure group but rather to a decrease in diameters after occlusion of the fistula. Blood flow velocity, IVC diameter, and shear stress were increased at 21 days in AVF mice compared with sham mice, although both velocity and shear stress decreased, and IVC diameter increased, as we followed the blood flow cranial from the AVF to above the renal veins (Fig. 5, C-E) .
Histological assessment was performed 150 -200 m above the AVF, in the infrarenal IVC (Fig. 6, A-C) , showed a thickened venous wall in mice with successful AVFs compared with a thinner venous wall in both preoperative and sham mice.
Quantification of the intima-media thickness of the venous limb of the AVF confirmed significant thickening (Fig. 6D) that was characterized by an increased number of ␣-actinpositive cells without any change in CD31-positive cells (Fig. 6E) .
Since ϳ33% of the AVFs patent on day 21 show ultrasound evidence of failure by day 42 (Fig. 3B) , we analyzed patent and failed AVFs at day 42 (Fig. 7, A and B) . Histology at the AVF site showed perianastomotic AVF tissue growth; this tissue was thin and had a lumen in patent AVFs (Fig. 7A) aorta and IVC in AVFs that failed (Fig. 7B) . These findings are similar to human AVFs that fail by perianastomotic neointimal hyperplasia.
DISCUSSION
The mouse AVF is a highly reproducible animal model that does not require advanced microsurgical skills. Here, we report that serial observations using Doppler ultrasound technology that identify a subpopulation (25%) of animals whose AVFs do not mature, e.g., occlude due to thrombosis or failure to dilate, by postoperative day 21; furthermore, of those AVFs that do mature, another subpopulation (33%) of animals develop perianastomotic thickening and AVF failure, similar to perianastomotic neointimal hyperplasia in human AVFs. As such, the mouse AVF is a novel model that recapitulates the clinical course of human AVF, exhibiting a reasonable rate of maturation (75%) as well as a reasonable long-term patency rate (67%) (2, 4, 7, 19, 21, 22) .
Although some aspects of this model are similar to previously described models, there are important differences. First, our study used mice rather than rats or larger animals that facilitate technical success of the surgical procedure (1, 5, 8, 12, 15, 16 ). An advantage of the mouse model is the availability of genetic strains and variants that can be used to host AVF and thus study its effects in animal models of disease. Second, although there are some studies (6, 10, 11, 17) that have performed AVF surgery on mice, these reports have generally been in the context of developing a model for right-sided heart failure, using larger-size needles (11, 17) . We used a 25-gauge needle to perform the puncture and were able to detect lower limb venous congestion from the additional arterial flow into the vena cava; however, we did not detect serious adverse events in the mice, consistent with the clinical safety of most AVFs in human patients. However, Fig. 3A shows the learning curve for the mouse model; these results showed that improved practice with cessation of bleeding improves the technical success of the procedure. The residual ϳ20% of cases that are technical failures are likely due to either the excessive force needed to stop the puncture hole bleeding, due to compression of the fistula tract, or due to low flow that becomes detectable at later times (Fig. 3B) . We continue to use compression for hemostasis as our experience with suture closure of the puncture site led to a much higher rate of vessel stenosis and fistula closure (data not shown). We believe that experience with the model is the best solution to improve the technical success rate.
In this model, there are both local and systemic effects due to the AVF. One of the interesting findings was the diminished shear stress above the renal veins. In sham mice, the increased suprarenal IVC diameter may be responsible for the relative diminution of shear stress compared with the infrarenal segment. Similarly, when the AVF is present, the tremendously increased flow (Fig. 5C, shaded bars) increases the infrarenal shear stress, which then diminishes in the increased diameter of the suprarenal IVC (Fig. 5E, shaded bars) . We believe that the large amount of renal vein flow into the suprarenal IVC stabilizes the infrarenal high-velocity turbulent flow due to the AVF, resulting in more laminar flow and accordingly lower mean velocities.
In summary, this model recapitulates aspects of the AVF that is created in human patients. Due to the scarce knowledge of both the maturation and failure that occur in human AVFs, this model may become a powerful tool to study the improvement of AVF outcomes.
Conclusions. The murine aortocaval model faithfully recapitulates the maturation and patency of the human AVF, with subgroups of animals failing to mature and, of those that do mature, another subgroup that fails in long-term followup. This model does not require advanced microsurgical skills, is straightforward to analyze, and has minimal system adverse effects. Therefore, this model should be useful in the study of AVF in animal models of disease.
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